197 related articles for article (PubMed ID: 8347500)
21. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study.
Gonzalez R; Ebbinghaus S; Henthorn TK; Miller D; Kraft AS
Melanoma Res; 1999 Dec; 9(6):599-606. PubMed ID: 10661772
[TBL] [Abstract][Full Text] [Related]
22. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium.
Kraft AS; Adler V; Hall P; Pettit GR; Benjamin WH; Briles DE
Cancer Res; 1992 Apr; 52(8):2143-7. PubMed ID: 1559218
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.
Scheid C; Prendiville J; Jayson G; Crowther D; Fox B; Pettit GR; Stern PL
Cancer Immunol Immunother; 1994 Oct; 39(4):223-30. PubMed ID: 7954524
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
25. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.
May WS; Sharkis SJ; Esa AH; Gebbia V; Kraft AS; Pettit GR; Sensenbrenner LL
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8483-7. PubMed ID: 3317410
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.
Armstrong DK; Blessing JA; Rader J; Sorosky JI;
Invest New Drugs; 2003 Nov; 21(4):453-7. PubMed ID: 14586213
[TBL] [Abstract][Full Text] [Related]
27. Phase II evaluation of bryostatin-1 in metastatic melanoma.
Bedikian AY; Plager C; Stewart JR; O'Brian CA; Herdman SK; Ross M; Papadopoulos N; Eton O; Ellerhorst J; Smith T
Melanoma Res; 2001 Apr; 11(2):183-8. PubMed ID: 11333129
[TBL] [Abstract][Full Text] [Related]
28. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
[TBL] [Abstract][Full Text] [Related]
29. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
Cole DJ; Sanda MG; Yang JC; Schwartzentruber DJ; Weber J; Ettinghausen SE; Pockaj BA; Kim HI; Levin RD; Pogrebniak HW
J Natl Cancer Inst; 1994 Jan; 86(1):39-45. PubMed ID: 8271281
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
[TBL] [Abstract][Full Text] [Related]
32. Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM).
Grant S; Pettit GR; McCrady C
Exp Hematol; 1992 Jan; 20(1):34-42. PubMed ID: 1374343
[TBL] [Abstract][Full Text] [Related]
33. Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
Thompson CH; Macaulay VM; O'Byrne KJ; Kemp GJ; Wilner SM; Talbot DC; Harris AL; Radda GK
Br J Cancer; 1996 May; 73(10):1161-5. PubMed ID: 8630272
[TBL] [Abstract][Full Text] [Related]
34. The clinical development of the bryostatins.
Clamp A; Jayson GC
Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
[TBL] [Abstract][Full Text] [Related]
35. The inhibitory effects of bryostatin 1 administration on the growth of rabbit papillomas.
Bodily JM; Hoopes DJ; Roeder BL; Gilbert SG; Pettit GR; Herald CL; Rollins DN; Robison RA
Cancer Lett; 1999 Feb; 136(1):67-74. PubMed ID: 10211941
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder JA; Shields AF; Zalupski M; Chaplen R; Heilbrun LK; Arlauskas P; Philip PA
Clin Cancer Res; 2001 Jan; 7(1):38-42. PubMed ID: 11205915
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
Varterasian ML; Pemberton PA; Hulburd K; Rodriguez DH; Murgo A; Al-Katib AM
Invest New Drugs; 2001; 19(3):245-7. PubMed ID: 11561682
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
39. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
Sessa C; Weigang-Köhler K; Pagani O; Greim G; Mora O; De Pas T; Burgess M; Weimer I; Johnson R
Eur J Cancer; 2002 Dec; 38(18):2388-96. PubMed ID: 12460783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]